Hear Robert A. Hauser, MD, MBA, FAAN, discuss the importance of tracking symptoms using the Parkinson’s disease diary, focusing on having patients experience a good response to medication for as much of the day as possible.
Although every person with PD is different, oral LD remains the cornerstone of treatment, including for those with early PD first initiating therapy for motor symptoms.
Extended-release carbidopa/levodopa (ER CD/LD) can often be mistaken for controlled-release carbidopa/levodopa (CR CD/LD). Take a look at how the two differ and how ER can sustain levodopa levels for longer. Also review updated guidelines supporting the use of levodopa as first-line therapy for patients with early Parkinson’s disease and motor symptoms. See what the American Academy of Neurology now recommends for your patients with Parkinson’s.
Read what movement disorders specialists, Salima Brillman, MD, Justin Martello, MD, FAAN, and Rajesh Pahwa, MD think about the limitations of immediate-release, and how CREXONT’s formulation has transformed innovation into duration for patients with Parkinson’s disease.
Sign up for the Expert Institute for Parkinson’s Disease newsletter to receive production information, educational tools, resources and more!